Skip to main content
Psyence Group Inc. logo

Psyence Group Inc. — Investor Relations & Filings

Ticker · PSYG ISIN · CA74449Q2053 LEI · 549300RPEOIVSD0MJC07 CSE Manufacturing
Open in API
Filings indexed 385 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country CA Canada
Listing CSE PSYG

About Psyence Group Inc.

https://psyence.com/

Psyence Group Inc. is a science-led life science biotechnology company focused on the research, cultivation, and production of natural psychedelics and nature-based compounds. The company develops innovative, safe, and effective solutions for mental health. Its core clinical division, Psyence Therapeutics (now part of Psyence Biomedical Ltd.), pioneers the use of natural psilocybin formulations and treatment protocols, primarily targeting anxiety and depression within the context of palliative care. Supporting this effort, the company operates one of the world's first federally licensed, ISO22000 certified psilocybin cultivation and production facilities. Furthermore, Psyence Function markets a range of non-psychoactive functional mushroom wellness products utilizing adaptogens.

Recent filings

Filing Released Lang Actions
Notice of meeting - English.pdf
Regulatory Filings
2026-04-29 English
Other material contracts - English.pdf
Management Reports Classification · 98% confidence The document is the Management’s Discussion and Analysis (MD&A) for the year ended December 31, 2025 (Form 51-102F1), containing detailed management commentary on financial results, operations, and business events. This matches the definition of a Management Reports filing (MDA). It is not merely an announcement of publication but the full MD&A text itself.
2026-04-24 English
News release - English.pdf
Capital/Financing Update Classification · 84% confidence The document is a detailed term sheet/prospectus-style offering for TD’s Series 3231F autocallable coupon notes, describing the issue date, maturity, coupon mechanics, auto-call feature, barrier levels, and other offering details. This is a direct financing transaction by the issuer and represents a capital-raising activity rather than an investor slide deck, financial report, or regulatory announcement. Therefore, it best fits the “Capital/Financing Update” category (CAP).
2026-04-24 English
News release - English.pdf
M&A Activity Classification · 90% confidence The document is a corporate news release announcing an amendment to a previously announced amalgamation agreement and outlining the proposed transaction (reverse takeover) between Psyence and GoldCoast, including updated share consolidation details and shareholder meeting information. It does not present financial results nor request votes for governance changes alone, but rather focuses on an M&A transaction. Therefore, this fits the M&A Activity category.
2026-04-24 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 85% confidence The document is a formal notice filed via SEDAR+ to exchanges and securities regulators regarding the Annual General and Special Meeting date and associated record dates for Psyence Group Inc. It does not contain proxy materials or presentation content itself, nor does it announce financial results, dividends, or M&A activity. This falls under a general regulatory announcement that does not fit other specific categories. Therefore, it is classified as a Regulatory Filing (RNS).
2026-03-31 English
News release - English.pdf
Regulatory Filings
2026-03-25 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.